Molnupiravir Shortage: What Providers and Prescribers Need to Know in 2026

Molnupiravir (Lagevrio) occupies a specific and important niche in the COVID-19 antiviral landscape: it is the only oral option that lacks clinically significant drug-drug interactions. For patients on complex polypharmacy regimens who cannot safely take Paxlovid, it is often the only viable oral antiviral. That makes its availability — and the frustrations your patients encounter when trying to fill it — a clinically meaningful problem.

This guide is designed to give providers a clear picture of the 2026 supply environment, practical prescribing tips, patient counseling guidance, and workflow recommendations for when your patient's prescription can't be filled.

The Current Molnupiravir Supply Situation (2026)

As of 2026, molnupiravir is not on the FDA Drug Shortage Database. Merck continues commercial manufacturing and distribution through standard pharmaceutical wholesalers (AmerisourceBergen, Cardinal Health, McKesson). However, pharmacy-level availability is inconsistent:

Large chain pharmacies (CVS, Walgreens, Walmart) are more likely to stock it, but individual locations vary.

Independent pharmacies may not carry it routinely but can often order it within 24 hours from their distributor.

Rural areas and small markets have the highest rates of localized unavailability.

COVID-19 seasonal surges (fall/winter) create temporary local stock depletion.

Why Molnupiravir Is a Low-Volume, High-Need Drug

NIH and IDSA guidelines position molnupiravir as a third-line agent — reserved for situations where Paxlovid and remdesivir are both inaccessible or inappropriate. The IDSA notes explicitly: "While molnupiravir lacks clinically significant drug-drug interactions, using it solely for convenience — without first evaluating whether nirmatrelvir/ritonavir or remdesivir can be used — is not recommended."

This guideline positioning creates a prescribing pattern where molnupiravir is: used infrequently (but critically when needed), ordered in small quantities by pharmacies, and often out of stock at the point of need. The paradox is that your highest-complexity patients — those most likely to need molnupiravir's interaction-free profile — are also the ones who can least afford a delay in treatment.

Clinical Criteria for Molnupiravir Prescribing in 2026

Under the current EUA, molnupiravir is authorized for:

Adults (≥18 years) only — NOT pediatric patients (bone and cartilage toxicity risk)

Mild to moderate COVID-19 with positive SARS-CoV-2 test

High risk for disease progression (age ≥50, obesity, diabetes, cardiovascular disease, immunocompromise, chronic kidney or lung disease)

Symptom onset within 5 days of the first dose

Alternative COVID-19 treatments (Paxlovid, remdesivir) are not accessible or clinically appropriate

Do not prescribe to: pregnant patients (potential fetal harm — boxed warning), patients under 18, those already hospitalized for COVID-19, or for prophylaxis.

Mandatory Prescribing Requirement: Pregnancy Status

The EUA requires prescribing providers to verify pregnancy status in females of childbearing potential before initiating molnupiravir. If prescribed to a pregnant patient, the provider must document that they communicated the known and potential benefits and risks, and inform the patient of Merck's pregnancy registry (1-877-888-4231 or pregnancyreporting.msd.com).

Contraception Counseling Requirements

Providers should counsel patients on contraception requirements:

Females of childbearing potential: Use reliable contraception during treatment and for 4 days after the final dose.

Males with partners of childbearing potential: Use reliable contraception during treatment and for at least 3 months after the final dose.

When a Patient Can't Fill Their Prescription: Your Clinical Checklist

When a patient calls your office saying they can't find molnupiravir:

Reassess Paxlovid candidacy — review the patient's full medication list using the Liverpool Drug Interaction tool or FDA label. A 5-day drug holiday on interacting medications (where clinically safe) may make Paxlovid feasible.

Refer for IV remdesivir — if the patient has access to a hospital or infusion center, a 3-day outpatient remdesivir course is a strong second-line option.

Direct to a pharmacy search service — recommend medfinder.com/providers for real-time pharmacy inventory checks, saving the patient time.

Widen the pharmacy search — ask your staff to call pharmacies within a 20-mile radius, or in regional hospital pharmacy networks.

Document the situation — chart that you attempted to prescribe molnupiravir and the patient was unable to access it, then document the alternative course of action.

Cost and Patient Assistance: What to Tell Patients

The retail cash price for molnupiravir is over $1,000 for a 5-day course. Counsel patients on available financial resources:

Merck Savings Coupon (commercial insurance): Eligible commercially insured patients may pay as little as $10. Patients register at lagevrio.com/patients/coupon.

Merck Patient Assistance Program: For uninsured or underinsured patients. Apply at merckhelps.com/LAGEVRIO or call 1-800-727-5400. Approved patients receive medication at no cost.

Medicare Part D: Lagevrio is typically placed on Tier 1 in most Part D formularies. Copays are generally low.

How medfinder Supports Your Patients

medfinder is a paid service that calls pharmacies near your patient to identify in-stock locations. Rather than having patients call pharmacy after pharmacy themselves — a process that wastes precious time in a 5-day window — providers can direct patients to medfinder.com/providers for a guided search. Results are texted directly to the patient, reducing the burden on both patient and provider staff.

Bottom Line for Providers

In 2026, molnupiravir remains a critical option for patients who cannot safely receive Paxlovid — but its inconsistent pharmacy availability makes proactive communication essential. Build pharmacy-finding support into your prescribing workflow, have a clear backup plan for patients who can't fill it, and ensure patients are counseled on cost-assistance programs before leaving your practice.